entertainment -WSS

entertainment

author：entertainment 2025-09-30 14:08:28 - browse：1726

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Obesity experts on risks of Wegovy, Ozempic weight loss drugs

WSS

Ask STAT: What do you want to know about ChatGPT in medicine?

The science behind Janet Jackson's pregnancy at 49

The stability of $0 premiums in Medicare Advantage

WHO recommends second malaria vaccine

Lawsuit highlights wrinkle for disputes over surprise medical bills

Death of patient in Alzheimer’s trial raises question of possible risks

focus

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

New oral drug delivery patch is modeled after octopus tentacles

Medicare details structure of new drug price negotiation program

Why we need to separate burnout from moral injury in health care

What does generative AI mean for health care? We asked experts

The Karikó problem: Lessons for funding basic research

Wildfire smoke exposes gaps in outdoor worker protections

Will an HIV vaccine ever be a reality?

Apple is now the first public company to be valued at $3 trillion

New oral drug delivery patch is modeled after octopus tentacles

hotspot

Cloning humans is technically possible. It's curious no one has tried

Will an HIV vaccine ever be a reality?

Nobel honors Karikó and Weissman's enduring partnership

IVG is promising — but it won’t replace IVF quite yet

WHO recommends second malaria vaccine

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

leisure time

focus

knowledge

explore